Pulmatrix Mails Definitive Proxy for Eos SENOLYTIX Reverse Merger Vote on October 16
PULM sits 39% above its 52-week low of $1.16.
Summary
Pulmatrix mailed its definitive proxy for the October 16 vote on its reverse merger with Eos SENOLYTIX, finalizing the exchange ratio and share issuance terms. Legacy Pulmatrix holders will own about 6% of the combined company.
Key Events · M&A and Partnerships · PULM
-
Definitive Proxy Mailed for October 16 Vote
On September 25, 2026, the definitive proxy statement was mailed, setting the special meeting for October 16, 2026 to approve the reverse merger with Eos SENOLYTIX.
-
Exchange Ratio Finalized at 8.55
Each share of Eos capital stock will convert into approximately 8.55 shares of Pulmatrix common stock, subject to adjustment based on capitalization at closing.
-
Legacy Holders Diluted to 6%
Pulmatrix securityholders will own approximately 6% of the combined company on a fully-diluted basis, with Eos securityholders owning the remaining 94%.
-
75.2 Million Shares to Be Issued
Pulmatrix expects to issue 54,359,630 shares to Eos stockholders and concurrent financing investors, plus 20,885,736 shares for new warrants, options, and RSUs, totaling 75,245,366 shares.
Analysis · PULM · Life Sciences
The definitive proxy statement for the October 16, 2026 special meeting has been mailed, setting the stage for a vote on Pulmatrix's reverse merger with Eos SENOLYTIX. The exchange ratio is now finalized at approximately 8.55 Pulmatrix shares per Eos share, leaving legacy Pulmatrix holders with only about 6% of the combined company. This deal is critical for Pulmatrix, which has just $2.2 million in cash and a going concern warning — without the merger, the board has stated it may liquidate. The proxy also seeks approval for a 1-for-2 to 1-for-10 reverse stock split to meet Nasdaq's $4.00 minimum bid price and an increase in authorized shares from 200 million to 250 million.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.7% of the 1013 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PULM was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.9M. The 52-week trading range was $1.16 to $5.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.